Michelle Delabye & Dominique Czaplinski

Articles translated into French by Michelle Delabye & Dominique Czaplinski

• Blue skies for Skyhawk: Positive news from Phase 1 trial for SKY-0515
• SURVEYOR opens the door for drugs that treat cognition
• Buckle in: Gene therapy AMT-130 appears to slow down signs of Huntington’s disease in Phase I/II clinical trial
• No pivot needed for PTC-518
• Positive news from Wave Life Sciences SELECT-HD trial
• Two birds, one stone: HTT-lowering drugs also target CAG expansions
• Understanding expansions at the single cell level
• Cry your eyes out: detecting huntingtin in tears
• How many is too many? Exploring the toxic CAG threshold in the Huntington’s disease brain
• Huntington's Disease Therapeutics Conference 2024 - Day 3
• Huntington's Disease Therapeutics Conference 2024 - Day 2
• Huntington's Disease Therapeutics Conference 2024 - Day 1
• Updates from PTC Therapeutics and uniQure on their huntingtin-lowering trials
• Huntington’s disease therapeutics conference 2023 - Day 2
• Huntington’s disease therapeutics conference 2023 - Day 3
• Huntington’s disease therapeutics conference 2023 - Day 1
• Roche Phase II GENERATION HD2 study underway
• Disappointing news from Novartis about branaplam and the VIBRANT-HD trial
• Update on the PTC Therapeutics PIVOT-HD Trial
• uniQure gets the green light to resume testing HD gene therapy
• Forward momentum for Roche and Wave in latest news about huntingtin-lowering trials
• Updates from uniQure about their gene therapy for Huntington's disease
• Artificial intelligence to save the day? How clever computers are helping us understand Huntington’s disease.
• A spoonful of branaplam helps the huntingtin go down
• Huntington’s disease therapeutics conference 2022 - Day 1
• Shining a spotlight on huntingtin: a tool to measure huntingtin-lowering in real time
• Oral drug may change the story for huntingtin lowering
• Finding the silver lining: an update on the Roche GENERATION-HD1 trial data
• GPR52: Exploring a new way to lower huntingtin
• Disappointing Results from Wave’s PRECISION-HD1 and 2 Trials
• Sad News from Roche and Ionis - ASO Trial Halted Early
• Updates from the EHDN Plenary Meeting 2020
• Huntington’s disease therapeutics conference 2020 - Day 1
• Huntington’s disease therapeutics conference 2020 - Day 2
• Huntington’s disease therapeutics conference 2020 - Day 3
• Details emerge of first Huntington’s disease gene therapy clinical trial
• Fresh Updates from First Huntingtin Lowering Study Publication
• An Updated Trial Design for Roche's Huntingtin Lowering Trial
• Huntington's disease therapeutics conference 2019 - Day 3
• Huntington's disease therapeutics conference 2019 - Day 2
• Huntington's disease therapeutics conference 2019 - Day 1
• Roche announces details of its 'pivotal' huntingtin-lowering study
• Huntington's disease therapeutics conference 2018 - day 1
• Huntington's disease therapeutics conference 2018 - day 2
• Huntington's disease therapeutics conference 2018 - day 3
• Success! ASO drug reduces levels of mutant protein in Huntington's disease patients
• Switch off the genome editor when you’re done
• Precision huntingtin-lowering drug trials target the mutant protein
• A step forward for gene editing: CRISPR-Cas9 and HD
• New study reveals a potential HD biomarker
• Update confirms Huntington's disease 'gene silencing' trial on track
• Huntington's Disease Therapeutics Conference 2017 - Day 1
• Huntington's Disease Therapeutics Conference 2017 - Day 2
• Huntington's Disease Therapeutics Conference 2017 - Day 3
• The benefits of migration, highlighted in Huntington's disease
• Huntingtin grabs a hammer: DNA repair in HD
• Weeding out the truth: can cannabis improve Huntington’s?
• Treasure your exceptions - using outliers to understand Huntington's disease onset and progression
• A powerful message: does a toxic RNA message molecule cause harm in Huntington's disease?
• Pfizer Amaryllis trial ends in disappointment: no improvement in Huntington's disease symptoms
• Sorry folks, the PRIDE-HD trial did NOT show that Pridopidine slows the progression of Huntington's disease
• Important advances in next generation genome editing tools for Huntington's Disease
• EuroBuzz 2016: The Euro-HD Network Meeting in The Hague
• Important drug targets yielded by new genetic study of HD
• Could a new "jaw-dropping" breakthrough help treat Huntington's Disease?
• Huntington's Disease Therapeutics Conference 2016 - day 3
• Through a Broader Lens: Looking at Non-Motor Symptoms in HD
• Harnessing the power of viruses to treat Huntington's disease
• Looking Past the Spin: Results from a Clinical Trial of Cysteamine
• Liftoff: First humans treated with gene silencing drugs for HD!
• A Few Bad Seeds: Using Brain Fluid to Grow Clumps in Brain Cells
• New tool to measure outcomes in Huntington’s Disease clinical trials
• Huge study reveals new 'genetic modifiers' of Huntington's disease
• A faulty filter? Blood vessel changes in Huntington's disease
• Measuring harmful huntingtin protein in the brain’s bath water
• Lighting the way: A new biomarker for Huntington’s disease
• Taking new targets to the bank: the DNA repair protein ‘ATM’ is overactive in Huntington's disease
• Building a Better Mouse(trap): A New Model of Huntington’s Disease
• 2015 Huntington's Disease Therapeutics Conference: Day 3
• 2015 Huntington's Disease Therapeutics Conference: Day 2
• 2015 Huntington's Disease Therapeutics Conference: Day 1
• Can this synthetic oil help feed the brain in Huntington's disease?
• Positive results announced for re-worked tetrabenazine drug in Huntington's disease
• Turning skin cells into brain cells: a Huntington's disease research breakthrough?
• Huntington's disease clinical trial announcement: huntingtin-lowering drug to enter Phase I trial in 2015
• Largest creatine clinical trial for Huntington's disease halted after 'futility' analysis
• A starring role for astrocytes in Huntington's disease?
• EuroBuzz 2014: day three
• EuroBuzz 2014: day two
• New results bring BDNF therapies into focus
• Illuminating the progression of Huntington’s disease
• Jumping genes: Huntington's disease protein invades brain transplants
• The brain in Huntington's disease: greater than the sum of its parts?
• Could HD be caused by amino acid deficiency?
• Huntington's Disease Therapeutics Conference 2014: day 3
• Huntington's Disease Therapeutics Conference 2014: day 2
• Huntington's Disease Therapeutics Conference 2014: day 1
• Does high-dose creatine "slow the onset" of Huntington's Disease?
• Could a 'brain shuttle' get Huntington's disease drugs to where they're needed?
• DNA shutdown proteins in Huntington's disease: More than meets the eye
• The sweet lowdown: Huntington's disease brains use sugar differently
• What the 'big neurodegeneration breakthrough' means for Huntington's disease
• 'Buzzilia' from the Huntington's Disease World Congress: day 4
• 'Buzzilia' from the Huntington's Disease World Congress: day 3
• 'Buzzilia' from the Huntington's Disease World Congress: day 2
• 2011 - a year in Huntington's disease research
• How long is too long? Rethinking the Huntington’s disease ‘gray area’
• Gene silencing drug safe in ALS patients... bring on Huntington's disease trials
• Splicing with danger: a new way of thinking about the harmful Huntington's disease protein
• A DNA repair protein modifies the stability of long CAG tracts in the Huntington's disease gene
• Landmark study puts Huntington's disease trials on TRACK
• The 'N17' region of huntingtin protein: an address label in Huntington's disease?
• No surprises in published results from HART study of Huntexil for Huntington's disease
• Gone fishing: protein network screen identifies new therapeutic targets in Huntington's disease
• Prominent Huntington's disease researcher "fabricated data" in grant applications
• Calming down the immune system helps Huntington's disease mice
• Prana Biotech publishes Huntington's disease animal model data for PBT2
• Closing the care gap: new guidelines for HD care
• Giving Huntington's disease the finger? Two teams report success for zinc-finger drugs in cells and mice
• Illuminating findings in blood cells from Huntington's disease patients
• HDBuzz Prize winner 2012: Deep brain stimulation for HD
• Lithium with a twist gets second chance for HD
• Shooting the messenger with single-stranded RNA gene silencing
• 'Induced' stem cells make exciting advances
• ASO gene silencing reaches further, lasts longer
• Exercise increases cellular recycling
• Phosphodiesterase inhibitors: new HD drugs entering trials soon
• Interview: CHDI's scientific team
• The HDBuzz Prize for young science writers
• Stem-cell neurons make the right connections
• 2012 Therapeutics Conference: a retrospective
• Special 'brain fat' injection helps HD mice
• Coming soon: HD Therapeutics Conference 2012
• HDYO! Huntington's Disease Youth Organization goes live
• Safety trials add crucial piece to gene silencing jigsaw
• Bone marrow transplantation in Huntington's Disease
• New experiments clarify the role of SIRT1 in HD - or do they?
• Double success for huntingtin RNAi gene silencing